November 18th 2024
More than half of US adults—approximately 137 million—are candidates for semaglutide based on diabetes, weight management, or cardiovascular prevention indications.
November 16th 2024
Weighing the Risks of Quitting Smoking and Obesity
One of the major concerns of people considering quitting smoking is whether they will gain weight. A new study has shown that may not need to be a concern and that the overall benefits to their health can outweigh the risks.
Improving the Safety of Diabetes Medications
As more diabetes drugs hit the market there are natural safety questions that come with these prescriptions. In recent years the US Food and Drug Administration has worked to increase the steps taken to ensure the safety of these drugs.
Bariatric Surgery Reduces Diabetes-Associated Vascular Disease in Obese Patients
March 6th 2015Bariatric surgery has been shown to reduce the long-term risk of diabetes-associated vascular disease in obese patients. According to study results presented at ENDO 2015, bariatric surgery reduced the risk of developing macrovascular events by 20% and reduced the risk of microvascular events by 50%.
Liraglutide Associated with Improved Glycemic Control in Overweight Patients with Prediabetes
March 6th 2015In overweight and obese individuals without diabetes, liraglutide 3.0 mg as an adjunct to diet and exercise was associated with greater reductions in fasting and postprandial glucose compared with diet and exercise alone.
Subspecialty Care and the Endocrinologist: Let's Get Virtual
March 3rd 2015Researchers from the Division of Endocrinology and Metabolism at the University of California, San Francisco analyzed the impact of virtual consultations on the spectrum and volume of endocrine consults. They measured access to endocrine care and downstream health care utilization. Their results indicate that virtual consultation offers many advantages for endocrinologists.
Mobilizing Immunotherapy for Type 1 Diabetes: On the Horizon
March 3rd 2015Type 1 diabetes mellitus is an autoimmune disease in which the body destroys all or part of its own roughly 1 billion β cells and cannot regenerate these critical endocrine components. Researchers have turned their attention to immunotherapies for treatment, postulating that targeting the immune system might restore β-cell function. It appears that combination therapies may be needed since clinical trial results have not met expectations based on animal studies.
The Use of Incretin-Based Therapy in Asian Patients with Diabetes
February 25th 2015Among the approximately 382 million people who have type 2 diabetes (T2DM) worldwide, approximately 20% live in South-East Asia and 65.1 million live in India. Asian populations are racially, demographically, culturally and socioeconomically heterogeneous. Researchers have identified unique trends in Asians diagnosed with T2DM.
Lipodystrophy: What HAART Has Taught Us
February 25th 2015The most common causes of lipodystrophy are insulin injection, antiretroviral drugs, and hereditary disorders. Some patients with insulin-related lipodystrophy also develop metabolic dysfunction, including insulin resistance, elevated free fatty acids level, abnormal adipocytokine secretion, and ectopic fat deposition.